BlackRock, Inc. 13D and 13G filings for MaxCyte, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-05 5:28 pm Sale |
2024-12-31 | 13G | MaxCyte, Inc. MXCT |
BlackRock Inc. BLK |
8,256,000 7.800% |
-2,169,244 (-20.81%) |
Filing |
| 2024-11-08 5:31 pm Unchanged |
2024-09-30 | 13G | MaxCyte, Inc. MXCT |
BlackRock Inc. BLK |
10,425,244 9.900% |
0 (Unchanged) |
Filing |
| 2024-10-21 4:11 pm Purchase |
2024-09-30 | 13G | MaxCyte, Inc. MXCT |
BlackRock Inc. BLK |
10,425,244 9.900% |
2,160,311 (+26.14%) |
Filing |
| 2024-01-26 11:49 am Purchase |
2023-12-31 | 13G | MaxCyte, Inc. MXCT |
BlackRock Inc. BLK |
8,264,933 8.000% |
531,720 (+6.88%) |
Filing |
| 2023-01-31 1:58 pm Purchase |
2022-12-31 | 13G | MaxCyte, Inc. MXCT |
BlackRock Inc. BLK |
7,733,213 7.600% |
890,253 (+13.01%) |
Filing |
| 2022-02-04 4:12 pm Purchase |
2021-12-31 | 13G | MaxCyte, Inc. MXCT |
BlackRock Inc. BLK |
6,842,960 6.800% |
6,842,960 (New Position) |
Filing |